BioCentury | Jul 2, 2012
Company News

Discgenics management update

...Gene/Cell therapy, Musculoskeletal Hired: Robert Wynalek as chief commercial officer and COO, formerly president at Osteotech Inc....
BioCentury | Nov 22, 2010
Company News

Medtronic, Osteotech deal

...Medtronic completed its previously announced acquisition of Osteotech for $6.50 per share in cash, or about...
...in cash, or about $123 million (see BioCentury, Aug. 23). Medtronic Inc. (NYSE:MDT), Minneapolis, Minn. Osteotech Inc....
BioCentury | Aug 23, 2010
Company News

Medtronic, Osteotech deal

...Medtronic will acquire Osteotech for $6.50 per share in cash, or about $123 million. The price...
...per share in cash, or about $123 million. The price is a 65% premium to Osteotech's...
...deal, which also is subject to approval by Osteotech shareholders. Medtronic Inc. (NYSE:MDT), Minneapolis, Minn. Osteotech Inc....
BioCentury | Aug 23, 2010
Finance

Regulatory milestones

...it will acquire postapproval research company United BioSource Corp. for about $730 million in cash. Osteotech Inc....
...would acquire the musculoskeletal company for $6.50 per share in cash, or about $123 million. Osteotech's...
...approved the deal, which is also subject to approval by its shareholders. For the week, Osteotech...
BioCentury | Aug 18, 2010
Company News

Medtronic to acquire Osteotech

...Medtronic Inc. (NYSE:MDT) will acquire Osteotech Inc. (NASDAQ:OSTE) for $6.50 per share in cash, or about $123...
...per share in cash, or about $123 million. The price is a 65% premium to Osteotech's...
...Osteotech's board has approved the deal, which is also subject to approval by Osteotech shareholders. Osteotech...
BioCentury | Aug 16, 2010
Company News

Osteotech dermatology, musculoskeletal news

...its advisor in 2009 to assist in identifying and evaluating strategic alternatives. At June 30, Osteotech...
...Osteotech markets biologic products for use in orthopedic, spinal, trauma, neurosurgical and oral/maxillofacial surgical procedures. Osteotech Inc....
BioCentury | Feb 1, 2010
Company News

Osteotech dermatology, musculoskeletal news

...be exercisable if a party acquires 15% or more of the company's outstanding common stock. Osteotech Inc....
BioCentury | Dec 21, 2009
Clinical News

DuraTech BioRegeneration Matrix regulatory update

...the dura mater in cranial surgical procedures. The product is an engineered human collagen biomaterial. Osteotech Inc....
BioCentury | Jul 6, 2009
Finance

2H09 Milestones

...Corp. (NASDAQ:GENZ)/JCR Pharmaceuticals Co. Ltd. (Osaka:4552) Prochymal Acute graft-versus-host disease (GvHD) Ph III data 3Q09 Osteotech Inc....
BioCentury | Jun 15, 2009
Clinical News

DuraTech BioRegeneration Matrix: Pivotal trial completed enrollment

...60 patients in a pivotal trial comparing DuraTech BioRegeneration Matrix vs. historical surgical procedure outcomes. Osteotech Inc....
Items per page:
1 - 10 of 55
BioCentury | Jul 2, 2012
Company News

Discgenics management update

...Gene/Cell therapy, Musculoskeletal Hired: Robert Wynalek as chief commercial officer and COO, formerly president at Osteotech Inc....
BioCentury | Nov 22, 2010
Company News

Medtronic, Osteotech deal

...Medtronic completed its previously announced acquisition of Osteotech for $6.50 per share in cash, or about...
...in cash, or about $123 million (see BioCentury, Aug. 23). Medtronic Inc. (NYSE:MDT), Minneapolis, Minn. Osteotech Inc....
BioCentury | Aug 23, 2010
Company News

Medtronic, Osteotech deal

...Medtronic will acquire Osteotech for $6.50 per share in cash, or about $123 million. The price...
...per share in cash, or about $123 million. The price is a 65% premium to Osteotech's...
...deal, which also is subject to approval by Osteotech shareholders. Medtronic Inc. (NYSE:MDT), Minneapolis, Minn. Osteotech Inc....
BioCentury | Aug 23, 2010
Finance

Regulatory milestones

...it will acquire postapproval research company United BioSource Corp. for about $730 million in cash. Osteotech Inc....
...would acquire the musculoskeletal company for $6.50 per share in cash, or about $123 million. Osteotech's...
...approved the deal, which is also subject to approval by its shareholders. For the week, Osteotech...
BioCentury | Aug 18, 2010
Company News

Medtronic to acquire Osteotech

...Medtronic Inc. (NYSE:MDT) will acquire Osteotech Inc. (NASDAQ:OSTE) for $6.50 per share in cash, or about $123...
...per share in cash, or about $123 million. The price is a 65% premium to Osteotech's...
...Osteotech's board has approved the deal, which is also subject to approval by Osteotech shareholders. Osteotech...
BioCentury | Aug 16, 2010
Company News

Osteotech dermatology, musculoskeletal news

...its advisor in 2009 to assist in identifying and evaluating strategic alternatives. At June 30, Osteotech...
...Osteotech markets biologic products for use in orthopedic, spinal, trauma, neurosurgical and oral/maxillofacial surgical procedures. Osteotech Inc....
BioCentury | Feb 1, 2010
Company News

Osteotech dermatology, musculoskeletal news

...be exercisable if a party acquires 15% or more of the company's outstanding common stock. Osteotech Inc....
BioCentury | Dec 21, 2009
Clinical News

DuraTech BioRegeneration Matrix regulatory update

...the dura mater in cranial surgical procedures. The product is an engineered human collagen biomaterial. Osteotech Inc....
BioCentury | Jul 6, 2009
Finance

2H09 Milestones

...Corp. (NASDAQ:GENZ)/JCR Pharmaceuticals Co. Ltd. (Osaka:4552) Prochymal Acute graft-versus-host disease (GvHD) Ph III data 3Q09 Osteotech Inc....
BioCentury | Jun 15, 2009
Clinical News

DuraTech BioRegeneration Matrix: Pivotal trial completed enrollment

...60 patients in a pivotal trial comparing DuraTech BioRegeneration Matrix vs. historical surgical procedure outcomes. Osteotech Inc....
Items per page:
1 - 10 of 55